Clinical

Dataset Information

0

MULTICENTER PHASE II STUDY FOR THE EVALUATION OF BEVACIZUMAB, OXALIPLATIN AND CAPECITABINE IN THE TREATMENT OF ELDERLY PATIENTS WITH ADVANCED COLORECTAL CANCER

ABSTRACT: Primary objectives: activity and toxicity of the proposed combination.

DISEASE(S): Gastrointestinal Disorders,Advanced Colorectal Cancer,Cancro Del Colon-retto Avanzato.

PROVIDER: 2527971 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Unknown First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study.
| S-EPMC4102952 | biostudies-literature
Unknown Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer.
| S-EPMC6023138 | biostudies-literature
Unknown A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.
| S-EPMC3607522 | biostudies-literature
Unknown A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.
| S-EPMC4106457 | biostudies-literature
Unknown Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer.
| S-EPMC11647033 | biostudies-literature
Unknown Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab.
| S-EPMC3639662 | biostudies-literature
Unknown Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
| S-EPMC4000321 | biostudies-literature
Unknown Long-Term Survival Outcomes of Elderly Patients Treated With S-1 or Capecitabine Plus Oxaliplatin for Stage II or III Gastric Cancer: A Multicenter Cohort Study.
| S-EPMC8980600 | biostudies-literature
Unknown Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
| S-EPMC4618621 | biostudies-literature
Unknown Prognostic and safety analysis of capecitabine monotherapy versus CapeOx (capecitabine plus oxaliplatin) in elderly patients with high-risk stage II and stage III MRD-negative colorectal cancer.
| S-EPMC12598343 | biostudies-literature